

Susana Cedres

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4822049/susana-cedres-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

749
citations

10
h-index

23
g-index

23
ext. papers

897
ext. citations

4.9
avg, IF

3.25
L-index

#	Paper	IF	Citations
22	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.. <i>Lancet Oncology, The</i> , 2022 , 23, 540-552	21.7	2
21	Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. <i>Scientific Reports</i> , 2021 , 11, 21357	4.9	0
20	SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). <i>Clinical and Translational Oncology</i> , 2021 , 23, 980-987	3.6	2
19	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021 , 125, 1561-1569	8.7	0
18	A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2020 , 38, 1588-1597	4.3	7
17	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020 , 22, 1390-1398	3.6	11
16	Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1702-1709	21.7	46
15	Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017 , 28, 2451-2457	10.3	43
14	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2016 , 96, 1-6	5.9	26
13	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2089-2099	8.9	100
12	Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). <i>PLoS ONE</i> , 2015 , 10, e0121071	3.7	160
11	Expression of WilmsWumor gene (WT1) is associated with survival in malignant pleural mesothelioma. <i>Clinical and Translational Oncology</i> , 2014 , 16, 776-82	3.6	12
10	Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7569-7569	2.2	4
9	Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2013 , 5, E35-7	2.6	2
8	Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (p).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8070-8070	2.2	
7	Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2012 , 14, 864-9	3.6	175
6	Rectal metastases from squamous cell carcinoma: a case report and review of the literature. <i>Case Reports in Medicine</i> , 2012 , 2012, 947524	0.7	6

5	Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7041-7041	2.2	
4	Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2011 , 12, 172-9	4.9	134
3	Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2010 , 12, 829-35	3.6	3
2	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. <i>Lung Cancer</i> , 2009 , 66, 257-61	5.9	16
1	Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (EOC). <i>Journal of Clinical Oncology</i> , 2007 , 25, 16007-16007	2.2	